A concise review on cobalt Schiff base complexes as anticancer agents

• Published in: Polyhedron Vol. 222; p. 115890
• Main Authors: Kar, Kanisha, Ghosh, Diya, Kabi, Bikash, Chandra, Arpita
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01.08.2022
• Subjects: Anticancer activity; Antiproliferative; Cobalt(II) & Cobalt(III); Cytotoxicity; Schiff base; Antiproliferative; ZFTFs; PR; SRB; Anticancer activity; Cytotoxicity; MTT; Schiff base; IC50; DMF; Bid; CCA; PDT; UV; GPX1; AO/EB; EAC; SOD; Cobalt(II) & Cobalt(III); EP; ER; PBMC; EMT; CAM; LNCaP(FGC); DNA; ROS; CAT; Bax; Bcl2; GRP-78; G/C; HER2; MMP-9
• ISSN: 0277-5387
• DOI: 10.1016/j.poly.2022.115890

This review chronologically summarizes the synthetic outline, structure, and anticancer potential of the cobalt(II) and cobalt(III) Schiff base complexes, as well as explains the requirement of selecting cobalt complexes over platinum and attempt to gain an insight of mechanism of action supporting the anticancer properties of the cobalt Schiff base complexes. [Display omitted] Research on metal-based chemotherapeutics gained tremendous impetus after the groundbreaking discovery of cisplatin and related complexes as potential anticancer agents. Unfortunately, applications of these platinum-based coordination complexes have become restricted owing to their toxicity and drug-resistant properties. Keeping these facts in mind, several groups studied cobalt complexes coordinated with Schiff base ligands. Cobalt has been found to be less hazardous to humans than platinum, and a cobalt(III) Schiff base complex, Doxovir, has advanced to the phase-II antiviral clinical trial as a cornerstone for future metallodrug research. This review chronologically summarizes the synthesis (outline), structure, and anticancer property of the cobalt(II) and cobalt(III) Schiff base complexes and tried to gain insight into the biochemical and biophysical properties of these complexes that can be correlated further to improve the design of novel anticancer agents with better clinical applicability.